Presentation is loading. Please wait.

Presentation is loading. Please wait.

ECG and histological findings of the heart in a 63-year-old man with metastatic melanoma who developed fulminant lymphocytic myocarditis following initial.

Published byFrida Karolina Andersson Modified over 5 years ago

Similar presentations

Presentation on theme: "ECG and histological findings of the heart in a 63-year-old man with metastatic melanoma who developed fulminant lymphocytic myocarditis following initial."— Presentation transcript:

1 ECG and histological findings of the heart in a 63-year-old man with metastatic melanoma who developed fulminant lymphocytic myocarditis following initial doses of nivolumab and ipilimumab and who developed complete heart block.36 Despite intense treatment (intravenous methylprednisolone 1 g/kg daily for 4 days plus infliximab 5 mg/kg), fatal complete heart block occurred. ECG and histological findings of the heart in a 63-year-old man with metastatic melanoma who developed fulminant lymphocytic myocarditis following initial doses of nivolumab and ipilimumab and who developed complete heart block.36 Despite intense treatment (intravenous methylprednisolone 1 g/kg daily for 4 days plus infliximab 5 mg/kg), fatal complete heart block occurred. Initial right bundle branch block (RBBB) and ST depression (A) progressed rapidly to complete heart block and cardiac arrest (B). Autopsy showed lymphocytic infiltration in myocardium (C) comprised CD3+ T cells (D), many of which were CD8+ lymphocytes (E) and CD68+ macrophages (F) (adapted with permission from Johnson et al36). Gilda Varricchi et al. ESMO Open 2017;2:e000247 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "ECG and histological findings of the heart in a 63-year-old man with metastatic melanoma who developed fulminant lymphocytic myocarditis following initial."

Similar presentations

Figure 1 (A) Chest computed tomography scans of the patient

Figure 1 (A) Chest computed tomography scans of the patient
Holter monitor ECG of a 65-year-old man showing marked ST depression of myocardial ischemia when the patient carried out his ordinary work routine as a.

Holter monitor ECG of a 65-year-old man showing marked ST depression of myocardial ischemia when the patient carried out his ordinary work routine as a.
Holter monitor ECG of a 65-year-old man showing marked ST depression of myocardial ischemia when the patient carried out his ordinary work routine as a.

Holter monitor ECG of a 65-year-old man showing marked ST depression of myocardial ischemia when the patient carried out his ordinary work routine as a.
Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.
Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.

Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Mechanism of CTLA-4-induced immunosuppression.

Mechanism of CTLA-4-induced immunosuppression.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
PRISMA study flow diagram

PRISMA study flow diagram

Similar presentations

Ads by Google